RecruitingPhase 1/2

Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Via Capsules for Intestinal Multidrug-resistant Bacteria Decolonization

Croatia48 participantsStarted 2025-07-28

Plain-language summary

The goal of this clinical trial is to learn if oral capsules containing lyophilized stool from healthy donors (fecal microbiota transplantation or FMT) can safely and effectively decolonize multidrug-resistant organisms (MDROs) from the intestines in adults. The main questions it aims to answer are: 1. Does FMT via oral capsules reduce or eliminate intestinal MDRO colonization? 2. What side effects or adverse events occur after taking FMT capsules? Researchers will compare FMT capsules to placebo capsules to see if FMT is effective and safe for decolonizing MDROs. Participants will: * Take either FMT capsules or placebo capsules by mouth * Attend 4 follow-up study visits over 6 months (180 days) for microbiological testing and safety monitoring * Provide stool samples and report any side effects

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥ 18 years, * rectal swab positive for MDRO (including but not limited to: CRE, ESBL-E, VRE) within a week of randomization, * capable of swallowing oral capsules, * willing to give informed consent Exclusion Criteria: * antibiotic treatment on the day of inclusion, * pregnant or breastfeeding, women of childbearing potential who are unwilling or unable to use an acceptable method of birth control, * patients with terminal diseases with expected life expectancy \< 6 months, * unwillingness to ingest the capsules, * a history of colectomy, present colostomy or ileostomy, * patients with the diagnosis/treatment of inflammatory or functional bowel disease, * patients with malignant bowel diseases, * absolute neutrophil count \< 500/mm3, * selective digestive decolonization with antibiotics within 6 months before randomization, * severe allergy to capsule components

What they're measuring

Efficacy (decolonization on visit 7)

Timeframe: Day 180 ± 7 from randomization

Trial details

NCT IDNCT07106580

SponsorUniversity of Rijeka

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07

Contact for this trial

Igor Rubinić, MD

+38551658513 igor.rubinic@uniri.hr